title: Prevalence of hematopoietic cell transplant survivors in the United States.
abstract: Advances in hematopoietic cell transplantation (HCT) have led to an increasing number of transplant survivors. To adequately support their healthcare needs, there is a need to know the prevalence of HCT survivors. We used data on 170,628 recipients of autologous and allogeneic HCT reported to the Center for International Blood and Marrow Transplant Research from 1968 to 2009 to estimate the current and future number of HCT survivors in the United States. Stacked cohort simulation models were used to estimate the number of HCT survivors in the United States in 2009 and to make projections for HCT survivors by the year 2030. There were 108,900 (range, 100,500 to 115,200) HCT survivors in the United States in 2009. This included 67,000 autologous HCT and 41,900 allogeneic HCT survivors. The number of HCT survivors is estimated to increase by 2.5 times by the year 2020 (242,000 survivors) and 5 times by the year 2030 (502,000 survivors). By 2030, the age at transplant will be < 18 years for 14% of all survivors (n = 64,000), 18 to 59 years for 61% survivors (n = 276,000), and 60 years and older for 25% of survivors (n = 113,000). In coming decades, a large number of individuals will be HCT survivors. Transplant center providers, hematologists, oncologists, primary care physicians, and other specialty providers will need to be familiar with the unique and complex health issues faced by this population.
authors.affiliation: National Marrow Donor Program, Minneapolis, Minnesota; Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota. Electronic address: nmajhail@nmdp.org.
authors.forename: Navneet S
authors.initials: NS
authors.lastname: Majhail
authors.forename: Li
authors.initials: L
authors.lastname: Tao
authors.forename: Christopher
authors.initials: C
authors.lastname: Bredeson
authors.forename: Stella
authors.initials: S
authors.lastname: Davies
authors.forename: Jason
authors.initials: J
authors.lastname: Dehn
authors.forename: James L
authors.initials: JL
authors.lastname: Gajewski
authors.forename: Theresa
authors.initials: T
authors.lastname: Hahn
authors.forename: Ann
authors.initials: A
authors.lastname: Jakubowski
authors.forename: Steven
authors.initials: S
authors.lastname: Joffe
authors.forename: Hillard M
authors.initials: HM
authors.lastname: Lazarus
authors.forename: Susan K
authors.initials: SK
authors.lastname: Parsons
authors.forename: Kim
authors.initials: K
authors.lastname: Robien
authors.forename: Stephanie J
authors.initials: SJ
authors.lastname: Lee
authors.forename: Karen M
authors.initials: KM
authors.lastname: Kuntz
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods / Q000401:mortality / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D017741:Survivors; D019172:Transplantation Conditioning / Q000379:methods / Q000401:mortality / Q000706:statistics & numerical data*; D014184:Transplantation, Homologous; D014481:United States; D055815:Young Adult
keywords: Allogeneic; Autologous; Hematopoietic cell transplantation; Prevalence; Survivors
references.citation: Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):561-70
references.pmid: 23535024
references.citation: J Clin Oncol. 2011 Jun 1;29(16):2230-9
references.pmid: 21464398
references.citation: Biol Blood Marrow Transplant. 2013 Jan;19(1):4-11
references.pmid: 23078785
references.citation: N Engl J Med. 1999 Jul 1;341(1):14-21
references.pmid: 10387937
references.citation: Br J Haematol. 2009 Oct;147(1):129-39
references.pmid: 19573079
references.citation: J Clin Oncol. 2012 Oct 20;30(30):3746-51
references.pmid: 23008296
references.citation: Biol Blood Marrow Transplant. 2013 Jul;19(7):1073-80
references.pmid: 23583827
references.citation: Bone Marrow Transplant. 2011 Mar;46(3):385-92
references.pmid: 20479710
references.citation: J Clin Oncol. 2010 Apr 10;28(11):1888-95
references.pmid: 20212247
references.citation: N Engl J Med. 2010 Nov 25;363(22):2091-101
references.pmid: 21105791
references.citation: J Clin Oncol. 2013 Jul 1;31(19):2437-49
references.pmid: 23715573
references.citation: J Clin Oncol. 2010 Feb 20;28(6):1011-6
references.pmid: 20065176
references.citation: Bone Marrow Transplant. 2013 Sep;48(9):1145-51
references.pmid: 23292238
references.citation: Biol Blood Marrow Transplant. 2013 Jul;19(7):1116-23
references.pmid: 23660172
references.citation: Biol Blood Marrow Transplant. 2009 Dec;15(12):1493-501
references.pmid: 19781658
references.citation: Blood. 2007 Nov 15;110(10):3784-92
references.pmid: 17671231
references.citation: Biol Blood Marrow Transplant. 2012 Mar;18(3):348-71
references.pmid: 22178693
references.citation: J Clin Oncol. 2011 Mar 1;29(7):805-13
references.pmid: 21220593
references.citation: Med Decis Making. 1993 Oct-Dec;13(4):322-38
references.pmid: 8246705
references.citation: Blood. 2011 Mar 17;117(11):3002-9
references.pmid: 21193694
references.citation: Blood. 2005 Jun 1;105(11):4215-22
references.pmid: 15701723
references.citation: Biol Blood Marrow Transplant. 2011 Jul;17(7):956-61
references.pmid: 21540121
references.citation: Br J Haematol. 2011 Aug;154(3):301-10
references.pmid: 21615719
references.citation: Bone Marrow Transplant. 2012 Mar;47(3):337-41
references.pmid: 22395764